Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193262 | SCV001361993 | uncertain significance | not specified | 2019-10-15 | criteria provided, single submitter | clinical testing | Variant summary: BRAF c.505-12A>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4e-06 in 250546 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.505-12A>G in individuals affected with Noonan Syndrome and Related Conditions and no experimental evidence demonstrating an impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Gene |
RCV001712884 | SCV001942659 | likely benign | not provided | 2020-07-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002069218 | SCV002441220 | likely benign | RASopathy | 2023-12-11 | criteria provided, single submitter | clinical testing |